Merck Announces Third-Quarter 2023 Financial Results

Sales Reflect Sustained Growth, Particularly in Oncology and Vaccines



Total Worldwide Sales Were $16.0 Billion, an Increase of 7% From Third Quarter 2022; Excluding LAGEVRIO, Growth Was 6%;...

Related Keywords

China ,United States ,Japan ,Canada ,Australia ,America ,Daiichi Sankyo ,Robertm Davis ,Adempas Verquvo ,Gardasil ,Linkedin ,Access To Health ,Exchange Commission ,European Union ,Youtube ,Merck Co Inc ,Orion Corporation ,Imago Biosciences Inc ,Facebook ,Statement Of Merck Co Inc ,European Society For Medical Oncology ,Sichuan Kelun Pharmaceutical Co Ltd ,Net Income Attributable To Merck Co Inc ,Instagram ,Merck Co ,Moderna Inc ,Clinical Program For Oral ,Prometheus Biosciences Inc ,Animal Health ,Drug Administration ,Japan Ministry Of Health ,European Commission Ec Approved ,Twitter ,Committee For Medicinal Products Human Use ,Alliance Revenue ,World Health Organization Group ,Accepted Accounting Principles ,Lorna Therapeutics ,Companion Animal ,Quarter Expense ,New Drug Applications ,European Society ,Medical Oncology ,Biologics License Application ,Prescription Drug User Fee Act ,Medicinal Products ,Human Use ,Patients With Resectable ,Neoadjuvant Treatment ,Then Continued ,Single Agent ,Adjuvant Treatment After Surgery ,Results From Phase ,Read Announcement ,Priority Review ,Priority Review Merck ,Certain Previously Treated Patients With Advanced ,Adjuvant Treatment ,Adults With ,High Risk ,Recurrence Following Complete Resection ,First Line Treatment ,Positive Advanced Gastric ,Gastroesophageal Junction ,Adenocarcinoma Expressing ,Negative Advanced Gastric ,Welfare Approved Lynparza Plus Abiraterone ,Single Agent After Surgery Reduced Risk ,Resectable Stage ,Padcev Reduced Risk ,Metastatic Urothelial Cancer ,Newly Diagnosed ,High Risk Locally Advanced Cervical Cancer ,Objective Response Rates Versus Everolimus ,Pathological Complete Response Rate ,Improved Disease Free Survival ,Activin Signaling Inhibitor ,Treat Adults With ,Presented New Analyses Supporting ,Promising Potential ,Its Investigational Medicine ,Initiated Phase ,Term Follow Up Data ,Sustained Immunogenicity ,High Risk Adult Kidney Transplant Recipients ,Day Dosing ,Prometheus Biosciences ,Imago Biosciences ,Canada Toll Free ,Looking Statement ,Securities Litigation Reform Act ,Annual Report ,Human Papillomavirus Quadrivalent ,Human Papillomavirus ,Rubella Virus Vaccine Live ,Varicella Virus Vaccine Live ,Conjugate Vaccine ,Before Taxes ,Net Income Attributable ,Income Attributable ,Common Share Assuming Dilution ,Shares Outstanding Assuming Dilution ,Divestiture Related Costs ,Tax Provision ,Common Share Assuming ,Total Vaccines ,Total Diabetes ,Includes Pharmaceutical ,Markets ,